The use of large-scale compound screening has become a key component of drug discovery projects in both the pharmaceutical and the biotechnological industries. More recently, these activities have also been embraced by the academic community as a major tool for chemical genomic activities. High-throughput screening (HTS) activities constitute a major step in the initial drug discovery efforts and involve the use of large quantities of biological reagents, hundreds of thousands to millions of compounds, and the utilization of expensive equipment. All these factors make it very important to evaluate in advance of the HTS campaign any potential issues related to reproducibility of the experimentation and the quality of the results obtained at the end of these very costly activities. In this article, the authors describe how GlaxoSmithKline (GSK) has addressed the need of a true validation of the HTS process before embarking in full HTS campaigns. They present 2 different aspects of the socalled validation process: (1) optimization of the HTS workflow and its validation as a quality process and (2) the statistical evaluation of the HTS, focusing on the reproducibility of results and the ability to distinguish active from nonactive compounds in a vast collection of samples. The authors describe a variety of reproducibility indexes that are either innovative or have been adapted from generic medical diagnostic screening strategies. In addition, they exemplify how these validation tools have been implemented in a number of case studies at GSK. (Journal of Biomolecular Screening 2009:66-76) 
INTRODUCTION T HE IN VITRO PHARMACOLOGICAL SCREENING IN EARLY
DISCOVERY has undergone critical changes in the past decade with the delivery of a mature discipline in pharmaceutical R&D, known as high-throughput screening (HTS). These changes have covered all aspects of the HTS process from compound management to the production and evaluation of hits.
The large-scale pharmacological screening has now been embraced by most of the pharmaceutical and biotechnological industry, as well as by the academic community in the chemical genomic field. Nowadays, compound libraries are typically above 1 million compounds in size and are easily accessible for diversity screening. Biochemical and cellular assays (screens) are carried out in high-density plates with final assay volumes in the range of one to tens of microliters per well. Assay plates are large-scale processed by robots or workstation platforms. The quantity and speed of data production have increased the benchmark values of the 1990s for throughput by more than 20-fold. A typical day of HTS operation provides more than 100,000 data points. Such volumes of data need to be properly managed, stored, and analyzed.
As these in-depth changes in "industrial" data production have settled down, an important requirement has emerged more strongly than ever-that is, "cost-efficient" management of the HTS processes. The new HTS systems need to minimize waste and rework, improve cycle time, and decrease the likelihood that product problems (poor-quality data) may be passed on to the therapeutic area teams. Organizations have tried to solve the problem by seeking and adapting traditional quality strategies, including quality control and quality assurance methods. The result is the "screening quality" culture in which "screening quality control" forms the core. 1, 2 In general, any quality system uses a variety of tools to detect and minimize assignable variability to a given process. It includes many procedures such as preventive maintenance, instrument function checks, and validation tests.
It is well established that validation of procedures is a key component of any quality strategy. 3 In the past years, different groups have noted the importance of HTS validation not only in the field compound screening arena but also more recently using large collections of RNA i . [4] [5] [6] [7] [8] In this article, we provide a comprehensive statistical analysis of the validation of HTS of file compounds.
Two sets of goals have to be addressed during HTS validation: the first one is about optimization of the HTS workflow and the evaluation of its quality as a process. Validated HTS procedures are the best way to provide cost-effective HTS campaigns. By optimized cost-effective HTS, we refer to the assurance that a specific HTS process will deliver data that meet predetermined specifications (i.e., validated parameters). We also refer to the investigation of predicted process error rates and their minimization. Every screen needs a specific quality planning. We define HTS validation as the statistical platform used to design the baseline quality goals and planning for each screening campaign.
The second group of key goals in validation focuses on the statistical evaluation of the screen reproducibility and diagnostic value of an HTS campaign. The screen diagnostic value or capability can be defined as the ability to accurately distinguish hits from nonhits in a large collection of samples. 9 The capability evaluation that we propose here is based on a variety of reproducibility indexes that are either innovative or have been adapted from generic screening strategies. 10 This article describes how we perform prospective HTS validation to produce operational screening protocols at GlaxoSmithKline. We provide the definitions of the statistical qualifiers as well as the software tools developed for that purpose. We also refer to the business rules that help decision making about the final acceptability of the process and their outputs.
Finally, we present some case examples. These will serve as means to discuss how our HTS validation helps to optimize results and also will illustrate how to set the baseline quality for the best efficiency of production. We also describe how validation predicts the key quality indicators obtained in subsequent HTS campaigns. Table 1 summarizes the main steps and objectives carried out during HTS validation.
MATERIALS AND METHODS
Step 0 refers to the initial test of reagents in the HTS laboratory at the bench. This is always done when the assay has been transferred from an external laboratory.
Step 1 is about the design of the operational procedure or workflow for the campaign. Factors that need to be considered include actual availability of resources and cycle time objectives. A clear judgment needs to be made about the key variables acting on the process to be validated. For instance, depending on the process design, the number of pipetting steps may not be so crucial compared with adding/not adding a lid to the plates or being/not being flexible for a certain incubation period. Normally, the most efficient processes have standardized workflows-for example, Ca 2+ mobilization assays carried out in a fluorescent imaging plate reader (FLIPR) or typical kinase assays. Nevertheless, a complete process standardization is not always possible due to the variety of conditions and formats that the screen might require. A clear working plan and workflow have to be decided before advancing to HTS validation. Further on, we focus on the optimization of individual equipment. Special attention is required for the validation of the liquid handler and reader protocols. First, we prepare several "DMSO plates," which are plates with positive controls (maximal signal; e.g., uninhibited enzyme reaction) and negative controls or blanks (background; e.g., substrate without enzyme or with inhibitor). Using both total signal and background, we can identify error in the pipetting units, and we eventually set the pipetting conditions of the liquid handler for the entire HTS campaign. This preautomated phase is in our experience absolutely critical, particularly when the HTS campaign is going to be attempted in 1536.
Slight differences in reagents or buffer composition (i.e., presence of glycerol, bovine serum albumin [BSA], DMSO, scintillation proximity assay [SPA] beads, cells, etc.) could affect liquid density, viscosity, or stability of reagents, and these factors could have a dramatic impact on the optimization of the pipetting variables. Some liquid handlers may offer from 10 to more than 20 variables of pipetting options, including pipetting speed, height, pretip soaking, sequence of reagent addition, delay between additions, quantity of partial volumes, mixing, tip washing, tip change, and so on. Setting a default collection of standard pipetting protocols is highly recommended to help with standardization and faster assay setup. These standard pipetting protocols can be obtained by using 2 or more reagents, including fluorescein as a probe (see Taylor et al. 11 for further details on standard operation procedures for liquid handling in HTS). In any case, each screen will further need a particular optimization of the default protocol-not only because every screen needs a proper and careful state-of-the-art pipetting procedure but also because the global schedule of the robotic platform or workstation will be conditioned by its duration. In terms of time, the global efficiency of the workflow relies on the optimization of the individual pieces, protocols, or subprocesses.
The objectives of steps 2 and 3 illustrated in Table 1 include not only making valid the HTS machinery and process but also testing statistical parameters of the assay, determining baseline values for monitoring quality during primary screening, and checking assay reproducibility and ability to properly classify hits and nonhits.
Simulating the continuous operation with runs of the appropriate length is strongly recommended, particularly when there is a high level of process automation. This can be achieved by running the protocol with empty plates and interleaving reaction plates at certain intervals. This test is important for assessing platform operation, reagent stability under platform environment, getting initial quality assessment of results (automated Z′), and confirming all the data-handling machinery.
Step 3 comprises running a validation collection of samples in triplicate. The validation set that we use at GlaxoSmithKline (GSK) contains close to 10,000 compounds representing a wide diversity of chemotypes present in the HTS collection. The general principles of the validation experimental design are that each compound is tested in triplicate, and plates are tested in random order. The standard concentration for validation is the same concentration that we use during the HTS campaign. Also important is that validation runs are independent and mimic production runs as close as possible. The length of the validation runs is adjusted by interjecting DMSO plates and/or empty plates in between sample plates.
Analytical and software tools for the validation set
Only plates with acceptable quality control (QC) as determined by GSK Screening Quality Control (SQC) software criteria are included in the validation analysis. The SQC software includes a variety of analytical tools for QC in HTS. During the validation stage, the SQC software provides information that is similar to that provided during the HTS campaign with complete information and recommendations on go/no-go decisions for each plate according to certain business rules. These business rules apply to different criteria, including intraplate Z′, variability and trends of controls, systematic errors in plates, and proportion of false positives and false negatives in control populations (see Martin et al. 2 for further details on GSK SQC software).
If a whole run fails or more than a given number of plates, then it is repeated after careful analysis of causes to avoid the same situation happening again in the repetition (and later in production).
A pattern recognition step is highly recommended before proceeding with any reproducibility analysis in validation (see Martin et al., 2 Root et al., 12 and Makarenkov et al. 13 for further details on pattern recognition and correction procedures). The purpose of a pattern recognition analysis is to detect systematic result bias present in plate areas before inferring any reproducibility analysis. A visual inspection of gross patterns using heat maps may be enough at this stage. Another level of analysis is required when the purpose is centered on the potential impact of a pattern correction. We show an example of this (case 3) in the next section.
Different parameters are used to give information about the power of the assay to classify samples. All the reproducibility indexes described are provided by VIT (Validation IT Tool), a GSK-developed software tool based on SpotFire. VIT codes all the graphical, numerical, and tabular information according to the specifications defined in this article.
In order to keep internal coherence with our information technology (IT) outputs and tables, we use the terms hit and inactive to refer to any sample that produces a response above Coma et al.
Table 1. Experimental Steps and Objectives in High-Throughput Screening (HTS) Validation
Step Experiment Objectives or below a threshold and that has not been confirmed by a subsequent experiment. We use the terms true hit (or true active) and true inactive to define confirmed activities. Any other term follows criteria according to the glossary of terms of the Society for Biomolecular Screening (SBS). 14 Reproducibility for the entire range of activity 1 . Average range among replicates (Rob AR)
where Rob is robust calculation (see Analytical Methods Committee 15 and Appendix section for details about robust algorithm). Max and min are the maximum and minimum values among triplicates or duplicates for each compound j.
The VIT software provides warning limits for classifying reproducibility as "good," "moderate," and "bad."
Intraclass correlation coefficient (ICC)
The ICC is a reliability measurement. It is used to quantify the similarity between various sets of repeated measurements (duplicate and triplicate data). It is defined as the ratio of the variance associated with the observations over the sum of the variance associated with observations plus the error variance. 2, 16 There are also warning limits to detect "poor correlation" according to the ICC index.
Reproducibility of inactives
The population of inactive samples is comprised in every validation run by all samples below the cutoff or threshold value. The objective is to assess consistency among the distributions obtained in each replicate and hence among the corresponding partial cutoffs i .
The cutoff is defined as a multiple of the standard deviation above the mean for the population of inactive samples (see Martin et al. 2 and Analytical Methods Committee 15 for further details on this matter).
There is a warning limit in VIT when the cutoff surpasses a defined limit in the 3 validation runs.
Reproducibility of potential actives
Each validation run is named V i , where i = 1, 2, or 3. Max, min, and mid are the maximum, minimum, and middle values among the 3 replicates for a compound.
Rob mean i is the robust mean of all samples of validation run V i . Rob SD i is the robust standard deviation of all samples of validation run V i .
Rob SD is the mean of the 3 Rob SD i . N 3x represents the total number of triplicates. Hit ni represents the number of hits in V i (i.e., samples above cutoff i ).
Our definitions for classifying a sample as a true active (TA) or true inactive (TI) according to its triplicate results are shown in Fig. 1 .
A false positive (FP) in run V i occurs when the max value of 1 triplicate for a compound is higher that the cutoff i , the mid and min values are below the cutoff i , and the max-mid values differ more than 2-fold from the Rob SD. An extreme false positive (EFP) occurs when max value of 1 triplicate has a normalized response above 70%.
A false negative (FN) in run V i occurs when min value of 1 triplicate is below the cutoff i , mid and max values are above the cutoff i , and mid-min values differ more than 2-fold from the Rob SD. An extreme false negative (EFN) occurs when min has a normalized response below 15%.
Equations (2) to (9) define all the relative indexes, including the true active rate (TAR), the predicted confirmation rate (PCR), the hit rate (HR), the false-negative rate (FNR), and the false-positive rate (FPR).
TAR for validation is defined as
where TA n is the total number of TA. 
where (TA > cut-off i ) n is the number of TA above cutoff i in validation run i. Predicted confirmation rate for validation is defined as
3. Hit rate for validation i (HR i ) is defined as HR i (%) = 100*Hit ni /N 3x .
Hit rate for validation is defined as HR = average (HR 1 , HR 2 , HR 3 ).
4. False-negative rate for validation i (FNR i ) is defined as FNR i (%) = 100*FN ni /TA n ,
where FN ni is the number of FN in run V i . False-negative rate for validation is defined as
5. False-positive rate for validation i (FPR i ) is defined as FPR i (%) = 100*FP ni /TI n ,
where FP ni is the number of FP in run V i , and TI n is the total number of TI. False-positive rate for validation is defined as FPR = average (FP 1 , FP 2 , FP 3 ).
Warning limits and go/no-go criteria
Most of the warnings limits as well as the go/no-go business rules for HTS validation were set after cost-benefit analysis made on a wide range of validation cases. The analysis was carried out by a multidisciplinary team in charge of the definition of the HTS validation specifications at GSK. Some other particular warnings (e.g., the ICC limit) are derived from the literature. 2, 16 Every warning is evaluated and conclusions documented in a validation report and shared at a peer review that precedes production. Those who implement the methods described in this article should follow a similar procedure that agrees with the tolerance limits for their own labs and ensures appropriate education about their meaning in the context of HTS.
RESULTS
The power of the HTS validation method is exemplified in Fig. 2 to 4 by the analysis of 3 different cases.
Case 1 results are summarized in Fig. 2 . The screen is based on a DNA-dependent enzyme test using a scintillation proximity assay. The workflow comprises 3 additions with 2 mixing steps (5 μL final assay volume). In this particular HTS, the assay design included a 10-min preincubation time, an 80-min reaction time, and 3 h for bead sedimentation. It requires the use of 1536-well plates, with plate lidding optional. Every plate spends 5 min in the reader. The period of the workflow under validation includes 10 h of full operation (throughput 70 × 1536-well plates per day). Fig. 2A shows how the kinetic reaction had a slower course in 1536-than in 384-well plates. A second unpredicted situation discovered in the validation process was a gradient effect observed in plates full of controls when laid on the robotic platform hotel for a given time. To solve this problem, we covered the plates with opaque lids. The pipetting requirements of the procedure were especially complex to refine. The best pipetting protocol got benchmark values of 9% to 11% coefficient of variation (CV) 0.7%-2.4% outliers when using fluoresceine solutions. Variation went up to 15% CV (1.7%-2.5% of outliers) when using full assay components.
Results of the validation runs following the automated workflow are depicted in Fig. 2B-G. Fig. 2B illustrates the distribution of the Z′ values for the controls included in the assay plates of the validation collection. Fig. 2C shows a heat map visualization of 1 plate with controls and DMSO in all wells (a "DMSO plate") as it was presented by the SQC software. The correlation scatterplots and the VIT parameter table are summarized in Fig. 2D-G . Results indicate that (a) the Z′ distribution is low centered and dispersed (mean Z′ = 0.44; SD Z′ = 0.12). The risk of plate QC failure due to low Z′ is more than 10%. The analysis of DMSO plates points out the variation of inactive wells as the main cause of Z′ dispersion. This is due to both random and extreme variation (CV of DMSO samples 15%-18%; 1.7% outliers). (b) There is a large standard deviation for the inactive population of samples, as denoted by the Rob SD i (17%-20%), the significant cutoff (>50%), and the robust average range (26%) values. (c) There is also a low "constitutive" or "true hit rate" for this target (true active rate <0.1%). (d) There are high result rates of false positives and extreme false positives, and as a consequence, the confirmation rate (CR) is too low (CR <10%). (e) False negatives are at high levels as well, although assurance is needed due to the low true hit rate found. Case 1 is an example of screen workflow that results in a poor diagnostic value due to insufficient quality and high process variability.
Case 2 is an opposite example where most of the statistical outputs indicate a good quality. Case 2 screen targets a bacterial enzyme. It is tested in a kinetic assay based on fluorescence intensity and carried out in a 1536-well plate format (5 μL final assay volume). Fig. 3A shows the reaction course in 1536 wells. The raw data used to normalize results during the HTS campaign are the slope of the reaction in each well. The standard error of the slope, the endpoint of the reaction, and the intercept points at time 0 were recorded and used for in-well quality control analysis. Case 2 involves 2 additions with no mixing requirements. It demands 15 min preincubation time, 30 min reaction time (room temperature), and 5 min for reading out. The workflow was sent for validation in a fully automated platform with 2 readers on-line. Throughput was 110 plates/day in a 10-h total operation time. Fig. 3B -G sums up the results obtained for the workflow validation of case 2, including the Z′ distribution (B), a heat map visualization of a DMSO plate (C), the scatterplots for the validation collection (D-F), and the VIT parameter table (G). Results indicate that (a) in terms of Z′, there is a very good assay performance (mean Z′ = 0.71, SD Z′ = 0.1); (b) process variation is kept below warning levels as the Rob SD i (11%-13%) and the robust average range (13%) values corroborate; and (c) all the reproducibility indicators render good quality as there are no significant rates of false positives and false negatives. The predictive confirmation rate is very good (PCR = 84%), with the active rate about 3% for a 40% significant cutoff. Case 3 is based on the data for an HTS searching for inhibitors of another bacterial metabolic enzyme that was measured by fluorescence intensity upon product generation. The the 3 copies of the validation collection. n i is the number of samples in each run; Rob Mean is the calculated robust mean for the population of inactives; Rob SD represents the calculated robust standard deviation for the population of inactives; cutoff i is the calculated cutoff for each validation run; Rob AR is the average range of the triplicates; ICC is the intraclass correlation coefficient; TAR (%) is the calculated true active rate; HR (%) is the calculated hit rate; PCR (%) is the calculated predicted confirmation rate; FPR (%) is the calculated false-positive rate; EFPR (%) is the calculated extreme false-positive rate; FNR (%) is the calculated false-negative rate; EFNR (%) is the calculated extreme false-negative rate. The last row of the table shows average values for the corresponding parameters. assay was fully automated with 2 readers in the platform. This case illustrates an example where the inspection and analysis of patterns in validation helped to make a better decision for the HTS campaign based on the comparison of the validation indexes. Fig. 4A represents a visual inspection of patterns using heat maps. Images in the left column in Fig. 4A show how the central areas of the plates are systematically giving higher values than the peripheral areas. The pattern was qualified, quantified, and mathematically corrected according to pattern correction algorithms developed at GSK. 2 The central column represents the mathematical model of the pattern, and images in the right column illustrate the results after applying the pattern recognition algorithm. Fig. 4B represents some of validation parameters with and without pattern correction. For this particular case, data indicate that pattern correction created a benefit for the global screen capability, not only by a slight enhancement on the predicted confirmation rate (63% to 65%) of the screen but also by a decrease of the significant cutoff (from 34% to 25% response) and an increase in the number of captured hits and true actives (hit rate from 1.1% to 2%, true active rate from 0.8% to 1.5%). (G) Validation IT Tool (VIT) table for the 3 validation runs. n i is the number of samples; r mean is the calculated robust mean for the population of inactives; r sd represents the calculated robust standard deviation for the population of inactives; cutoff i is the calculated cutoff for each validation run; rob AR is the average range of the triplicates; ICC is the intraclass correlation coefficient; TAR (%) is the calculated true active rate; HR (%) is the calculated hit rate; PCR (%) is the calculated predicted confirmation rate; FPR (%) is the calculated false-positive rate; EFPR (%) is the calculated extreme false-positive rate; FNR (%) is the calculated false-negative rate; EFNR (%) is the calculated extreme false-negative rate. The last row of the table shows average values for the corresponding parameters. examples of ordinary screen formats in HTS, including enzymatic, receptor binding, and Ca 2+ mobilization cell-based assays. As can be observed in Fig. 5 , there is a good correlation for hit rate and cutoff values and only moderate correlation of Z′ and confirmation rate values. It should be noted that the values for validation presented here are taken from the validation runs closer to production. Quite often, a first iteration unveils issues that require significant changes of procedures, reagents, and/or instruments. It is our practice to repeat the validation with the final process to be used in HTS prior to production. Nevertheless, the HTS process is not frozen after start, and tweaks are implemented if quality control results identify any undesirable trend or production failure during the HTS campaign.
Process Validation and Screen Reproducibility in High-Throughput Screening
The modest correlation of Z′ in validation and in HTS may well be a reflection of the variability interbatch of high controls for many assays such as cellular assays. As reflected in other indexes such as cutoff or hit rate, even the highest Z′ discrepancies (more than 0.15 Z′ units for 3 of 16 cases) have a limited influence in the HTS output.
The observed variation of inactive samples (i.e., SD i ) can be theoretically considered as the sum of various components. These factors include actual assay variability, organic load (i.e., matrix effect of compounds), and process variability sensu stricto. Assuming that the two first elements are kept constant for a given assay configuration, Rob SD i changes can be associated with changes of variation due to process. In this sense, the cutoff obtained in validation is an indirect quality indicator of process variation for a given screen workflow. The good correlation observed for this parameter is shown in Fig. 5C . It indicates that the validation procedure generally reflects the major components of process variation that can be expected in the massive HTS campaign. This fact is confirmed by the good correlation obtained for hit rate in Fig. 5B .
Confirmation rate is the composite of 2 independent variables: number of true actives detected as hits and number of false positives. The lack of correlation in the middle range of the plot in Fig. 5D can be traced to the behavior of both components. Surprisingly, the true active rate is predicted very well in validation (R 2 = 0.93), whereas the false-positive rate is not (R 2 = 0.37). In terms of prediction of the true active rate, we always understood that the coverage of chemical diversity in the HTS collection within the validation set was limited, thus allowing only a rough estimate of the final true active rate. Moreover, the GSK validation set was built from the HTS collection handled by GSK in 2002. Since then, the collection size has quadrupled, reaching in 2008 up to 2 million compounds; this growth has come mainly from addition of chemotypes not represented previously. The examples shared in Fig. 5 correspond to screens run in 2004-2007 against collections ranging from 800,000 to 1,500,000 chemical compounds with new diversity not represented in the validation set. It is thus unexpected to observe an almost perfect correlation of the true active rate between validation and HTS. True hits of interest are rare and far apart; therefore, this finding indicates that lists of hits confirming in the HTS assay (true actives) are populated by artifacts, nonspecific hits, nuisance compounds, and so on, which are predictable per target, together with a small population of hits from the few series of prospective interest that need to be identified in subsequent steps from a forest of undesirable hits. This observation has been reported recently for a betalactamase screen 17 in which most hits were found to be aggregators. Interestingly, nuisance effects such as aggregation seem to show up in different degrees for different targets as inferred by the spread of hit rate values observed in Fig. 5B (HR from 0.5% to 3%). For the conspicuous cases (HR >4%), it may be just an indirect reflection of the probabilistic algorithms used to infer cutoff, from the calculated Rob SD i , because the 3 cases with the highest hit rates correspond to the ones with the lowest cutoffs (cutoff <10%).
On the other hand, the lack of correlation for the false-positive rate can be indicative of the fact that the validation false-positive rate is analyzed carefully and triggers measures to reduce it in production. This is achieved often (7 out of 14 cases reported). But there are also new sources of variability arising in production that were not observed in validation or simply are an exacerbation of the same variability (6 out of 14 cases reported).
DISCUSSION
Despite the extensive use of HTS in the pharmaceutical and biotechnological industry, there have been few reports about the standardization of methods for validation and quality control. [4] [5] [6] [7] [8] At GSK, we have made a big investment in highly automated compound stores and screening platforms in factory-style facilities. Along with these acquisitions, we have developed the appropriate tools to help with management of these facilities, including a number of quality control tools. This is the first article of a few that will show how early discovery at GSK is benefiting from the implementation of quality assurance and process improvement practices.
In the HTS environment, a production day means testing 100,000 to 300,000 compounds in one or various runs. That could represent as much as 20% of the screening campaign, which is a significant investment in reagents, lab supplies, compounds, and so forth. This industrial dimension of the HTS reality can only be accomplished efficiently if it is based on well-grounded processes. Process validation in HTS is a challenge due to the many sources of variability of every automated assay and the peculiar behavior of the biological reagents used in every new campaign. Instrumentation used in early discovery is often based on very innovative functionality rather than on reliability. Moreover, multiple assay technologies are typically required to allow screening of unrelated targets that confirm typical drug discovery portfolios. All these circumstances make the design of the HTS production lines very heterogeneous in terms of equipment and level of automation and preclude simple application of manufacturing principles in a typical HTS facility. 2 It is therefore extremely important to carry out a very detailed analysis of the HTS production for each particular assay, not only from the point of view of instrument reliability but also from the point of view of final assay quality.
In this article, we have described an HTS validation method based on a step-by-step procedure. The mathematical basis is founded on the statistics for screening tests, including original approaches developed from the information of a triplicate experimental design. The examples shown have demonstrated how effective this method can be applied not only to validate an HTS procedure as a whole but also to make a diagnosis on particular quality aspects and therefore work on quality improvement. The parameters that we have chosen have been defined to provide a good control of the HTS process, delivering very useful information for decision making. These parameters, some of them unrelated, have demonstrated internal coherence, and they allow us to successfully establish warning alarms (i.e., go/no-go criteria) based on the absolute and relative values. We have also demonstrated that they present an objective view about the capability of the HTS process under evaluation.
It is also worth highlighting the importance of the experimental design in validation with special emphasis on practical restrictions of the process. Appropriate sampling, randomization, and independent experimentation must be carried out to ensure an adequate diagnosis.
In summary, we believe that the time spent in carrying out a detailed analysis of the process, together with a good statistical validation of the HTS, helps to obtain better results and aids the screening scientists in knowing when to "turn the green light on" for a particular HTS.
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APPENDIX Outline of Robust Statistic Algorithm
Below is a step-by-step outline of how the robust algorithm proposed by the Analytical Methods Committee 15 works:
1. The initial average (μ) is estimated from the median (50th percentile) of the data. The initial standard deviation (σ) is estimated from 1.48*MAD. The median absolute difference (MAD) represents the median difference obtained by calculating the absolute difference of each observation from the median. 2. A set of upper and lower cutoff limits are calculated, and values outside this range are defined as outliers. The top cutoff is calculated as μ + c*σ, and the bottom cutoff is μ -c*σ, where c is a tuning constant. The tuning constant determines the sensitivity of the algorithm and is based on the expected number of outliers. The tuning constant should be a value between 1 and 2, and the lower it is, the more sensitive the algorithm. For our purposes, the tuning constant has been set at 1.5. 3. All the values larger than the top cutoff are replaced by the top cutoff value, and all the values lower than the lower cutoff are replaced by the lower cutoff value. 4. The new values for the average and standard deviation are calculated from these adjusted data. The new μ (no longer the median) is the arithmetic average of the data, and the new σ is calculated as , where , where N is a standard normal deviate.
Note: when c = 1.5, β = 0.778. Our estimate of σ is adjusted upwards because by setting values equal to the upper and lower cutoff, as defined in step 3, we potentially have a number of observations that are identical, and this gives a downward biased estimate of σ. Hence, we have to correct for this bias.
5. Go back to step 2 and repeat with the new estimates of μ and σ until convergence is met. Convergence is met when σ is <1% different from the last iteration (note: you would also want to enter a maximum number of iterations so that the program cannot get stuck in a never-ending loop). 
